EMA management board nominates Rasi as exec director; FDA approves Allergan's Juvederm in lips;

@FiercePharma: Sun Pharmaceutical's Shanghvi drops from top spot in Forbes India rich list. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: ICYMI: Merck KGaA counts on Latin America to power consumer-health future. Article | Follow @CarlyHFierce

> The European Medicines Agency's (EMA) management board has nominated Guido Rasi as its executive director. Release

> The FDA has approved Allergan's Juvederm Ultra XC for use in the lips. Release

> Hi-Tech Pharmaceuticals has filed a lawsuit against Dynamic Sports Nutrition over allegations of Racketeer Influenced and Corrupt Organizations (RICO), trademark infringement and deceptive advertising. Release

> Association of the British Pharmaceutical Industry (ABPI) CEO Stephen Whitehead has left the organization. Report

> Early medication-fill patterns can predict future adherence, a study from the CVS Health Research Institute and Brigham and Women's Hospital says. More

> Bayer's plastics business whittled down its IPO's planned share sale to €1.5 billion ($1.7 billion) from €2.5 billion, in part because of the impact of the emissions scandal surrounding Volkswagen, a major customer. Report

Medical Device News

@FierceMedDev: From FierceDrugDelivery: Intarcia buys Phoundry in search of additional diabetes drugs for its subdermal drug pump. Story | Follow @FierceMedDev

@VarunSaxena2: Study: Oraya radiation tech reduces need for eye injections in AMD patients. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: New Hampshire AG launches investigation into opioid marketing. Article | Follow @EmilyWFierce

> Neuravi ready to take on Medtronic, Stryker in burgeoning market for devices to fight stroke. More

Biotech News

@FierceBiotech: Fierce's coverage of the Martin Shkreli saga. More | Follow @FierceBiotech

@JohnCFierce: Ladies and gentlemen, the 2015 Fierce 15. Special report | Follow @JohnCFierce

> Sarepta gets creative in bolstering its case for quick eteplirsen approval. Report

> Genentech embraces Arvinas with $300M tie-up on protein degradation. Story

> Facing a crisis, Xoma buys time with a $517M Novartis deal. Article

Vaccines News

> Novavax's RSV jab protects infants in PhII, nets $89M Gates Foundation grant. Article

> Advaxis targets HER2 cancers with first-in-human vaccine trial. Story

> BiondVax, EU's UNISEC team up for universal flu jab PhIIb. More

> PRA Health joins with clinical research network to improve vaccine studies. Item

> NewLink wins $26.1M in government funding to advance Ebola vaccine. Report

CRO News

> Frontage doubles its bioanalytics space. Item

> Accelovance snags another Big Pharma cancer vet to boost its onco profile. Report

> PRA partners up to accelerate vaccine R&D. More

> Patheon rebrands with a $100M IPO in the works. Story

> Chiltern expands in diabetes after a big buyout. Article

Pharma Manufacturing News

> Siegfried completes $302M deal for BASF API plants. News

> EPA presents Pfizer with $194M bill to cleanup former American Cyanide site. Report

> Abbott said to expand manufacturing, other operations in India. Story

> Will a desktop device that synthesizes lidocaine revolutionize pharma manufacturing? More

> Hovione set to expand its NJ facility and add new spray dryer. Article

Pharma Asia News

> China slaps Fosun Pharma unit with small fine for anti-monopoly violations. News

> Singapore's Biosensors launches sales of BMX-J stent in key Japan market. More

> Australia's Paranta Biosciences raises A$7M for PhI of cystic fibrosis candidate. Report

> China biotech CARsgen inks deal with Shanghai Cancer Institute on candidate focus. Story

> MSF campaigns at UN summit meeting to ease pressure on India's drug IP policies. Article

And Finally... Deleted quality tests in China have put the FDA on notice. Report

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.